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Intravascular versus surface cooling for
targeted temperature management after
out-of-hospital cardiac arrest – an analysis
of the TTM trial data
Guy W. Glover1,20*, Richard M. Thomas2, George Vamvakas3, Nawaf Al-Subaie4, Jules Cranshaw5, Andrew Walden6,
Matthew P. Wise7, Marlies Ostermann1, Emma Thomas-Jones8, Tobias Cronberg9, David Erlinge10, Yvan Gasche11,
Christian Hassager12, Janneke Horn13, Jesper Kjaergaard12, Michael Kuiper14, Tommaso Pellis15, Pascal Stammet16,
Michael Wanscher12, Jørn Wetterslev17, Hans Friberg18 and Niklas Nielsen19
Abstract
Background: Targeted temperature management is recommended after out-of-hospital cardiac arrest and may be
achieved using a variety of cooling devices. This study was conducted to explore the performance and outcomes
for intravascular versus surface devices for targeted temperature management after out-of-hospital cardiac arrest.
Method: A retrospective analysis of data from the Targeted Temperature Management trial. N = 934. A total of 240
patients (26%) managed with intravascular versus 694 (74%) with surface devices. Devices were assessed for speed
and precision during the induction, maintenance and rewarming phases in addition to adverse events. All-cause
mortality, as well as a composite of poor neurological function or death, as evaluated by the Cerebral Performance
Category and modified Rankin scale were analysed.
Results: For patients managed at 33 °C there was no difference between intravascular and surface groups in the
median time taken to achieve target temperature (210 [interquartile range (IQR) 180] minutes vs. 240 [IQR 180]
minutes, p = 0.58), maximum rate of cooling (1.0 [0.7] vs. 1.0 [0.9] °C/hr, p = 0.44), the number of patients who
reached target temperature (within 4 hours (65% vs. 60%, p = 0.30); or ever (100% vs. 97%, p = 0.47), or episodes
of overcooling (8% vs. 34%, p = 0.15). In the maintenance phase, cumulative temperature deviation (median 3.2
[IQR 5.0] °C hr vs. 9.3 [IQR 8.0] °C hr, p = <0.001), number of patients ever out of range (57.0% vs. 91.5%, p = 0.006)
and median time out of range (1 [IQR 4.0] hours vs. 8.0 [IQR 9.0] hours, p = <0.001) were all significantly greater in
the surface group although there was no difference in the occurrence of pyrexia. Adverse events were not different
between intravascular and surface groups. There was no statistically significant difference in mortality (intravascular
46.3% vs. surface 50.0%; p = 0.32), Cerebral Performance Category scale 3–5 (49.0% vs. 54.3%; p = 0.18) or modified
Rankin scale 4–6 (49.0% vs. 53.0%; p = 0.48).
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Conclusions: Intravascular and surface cooling was equally effective during induction of mild hypothermia.
However, surface cooling was associated with less precision during the maintenance phase. There was no
difference in adverse events, mortality or poor neurological outcomes between patients treated with
intravascular and surface cooling devices.
Trial registration: TTM trial ClinicalTrials.gov number https://clinicaltrials.gov/ct2/show/
NCT01020916NCT01020916; 25 November 2009
Keywords: Temperature, Hypothermia, Induced, Out-of-hospital cardiac arrest, Fever, Critical care, Shivering,
Brain injuries
Background
Targeted temperature management (TTM) may be indi-
cated in patients who remain comatose following return
of spontaneous circulation (ROSC) after out-of-hospital
cardiac arrest (OHCA) [1, 2].
TTM may be delivered by conventional or active
methods. Conventional methods include exposure, cold
intravenous fluids or ice slurry/proprietary cooling pads
[3–5]. Active methods are microprocessor-controlled
devices where the thermal energy is regulated by the
patient’s temperature, via a closed-feedback loop, deliv-
ering a programmed rate of temperature change and/or
target temperature. Active devices may be invasive/intra-
vascular (IV) catheters [6–8] or non-invasive/surface
devices (SFC), such as water-circulating blankets [9, 10]
or hydrogel pads [11, 12]. Cooling methods have been
reviewed comprehensively [4, 13–15].
TTM is divided into induction, maintenance, rewarm-
ing and fever control phases. Ideal devices achieve target
temperature quickly, allow for accurate maintenance and
slow, controlled rewarming. Conventional methods are
associated with overcooling and rebound hyperthermia
[16–18]. Active devices deliver more rapid induction,
with less temperature variation compared to conven-
tional [19–22], however, there may be significant differ-
ences in performance and adverse effects between SFC
and IV [11, 19, 23–27]. IV and SFC cooling may be
mechanistically different. IV cooling of circulating blood
could be likened to convective cooling. Whilst SFC also
relies on perfusion to transfer cold from the periphery to
the core, this will be affected by vasoconstriction and
there may be a significant element of conductive cooling.
Aside from any differences in controlling core body
temperature, there may be other effects. The direct con-
tact between the cold catheter and blood is non-
physiological; this could have effects on blood rheology
[28], which could be harmful in the context of myocar-
dial and cerebral ischaemia; at the same time, direct
circulation of cold blood into the right heart may have a
protective effect on the myocardium [29]. In comparison
SFC cooling is more ‘physiological’. The human body is
conditioned to receive changes in thermal input from
the environment primarily through the skin, and any
homeostatic mechanisms are designed to respond to this
type of thermal challenge.
The aim of this study was to investigate IV versus SFC
devices for TTM after OHCA. Our hypothesis was that
there is no difference in TTM performance, adverse
events or patient-centred outcomes.
Methods
A post hoc analysis of data from the Targeted
Temperature Management at 33 °C versus 36 °C after
Cardiac Arrest trial (TTM trial; NCT01020916) [30].
This randomized controlled trial of two levels of
temperature management after OHCA recruited 950
patients in 36 centres in Europe and Australia between
November 2010 and January 2013. The TTM trial proto-
col was approved by ethics committees in each partici-
pating country, and informed consent was waived or was
obtained according to national legislation, in line with
the Helsinki declaration. The trial demonstrated no
difference in all-cause mortality at the end of the TTM
trial.
Adult patients resuscitated from OHCA of a presumed
cardiac cause, who remained unconscious, were included
in the TTM trial. All patients were sedated and received
invasive mechanical ventilation. Core temperature was
measured primarily via a urinary catheter. Temperature
was managed with either an IV or SFC system according
to centre preference. Centres could use one or both
types of device but the type had to be decided and
recorded in the case report form prior to randomization.
The intervention was divided into three periods (a)
achievement of target temperature (4 hours); (b) mainten-
ance of target temperature (24 hours); and (c) rewarming
to 37 °C (8 hours). Following randomization, immediate
measures were taken to achieve the target temperature.
For patients allocated to 36 °C whose initial temperature
was below 36 °C, the temperature was allowed to passively
rise before it was maintained at target. Twenty-eight hours
after the start of the intervention, the device was set to
raise the temperature to 37 °C, with a maximum speed of
0.5 °C/hour. After 36 hours, sedation was discontinued or
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tapered and the patients were allowed to recover. Other
aspects of patient management were according to stand-
ard practice.
Exclusions from this study were (i) patients with-
drawn without receiving an intervention (ii) patients
with device type not recorded (iii) patients with no
initial temperature recorded (iv) patients whose
initial temperature was below, or within 1 °C of the
allocated target (excluded from induction analysis)
(v) patients who were rewarmed early (excluded
from maintenance analysis) (vi) patients who died
during the intervention (excluded from analysis of
performance and adverse events but not from
mortality).
Performance was analysed as follows:
Induction (33 °C group)
i. Maximum cooling rate
ii. Time from randomization to target temperature.
The temperature of 33.5 °C was chosen, halfway
between the trial target and the upper limit
recommended by the International Liaison
Committee on Resuscitation (I LCOR) of 34 °C
(2010 recommendations) [31]
iii. Number of patients achieving 33.5 °C
iv. Episodes of overcooling (temperature ≤32.5 °C
during the first 8 hours; a pragmatic value between
the trial target and the lower limit recommended by
ILCOR)
Maintenance and rewarming phase (33 °C and 36 °C
groups)
i. Cumulative deviation from target temperature
(magnitude × duration of deviation)
ii. Number of patients with temperature reading +/−0.5
°C out of range
iii. Time out of range
iv. Number of patients with temperature ≥37.5 °C
Adverse events were defined according to the TTM
trial protocol [32]. Patient-centred outcomes from
the TTM trial were also assessed; all-cause mortality
through to the end of the trial, and the composite of
poor neurological function or death at 180 days, as
evaluated with the Cerebral Performance Category
(CPC) scale 3–5 and the modified Rankin scale
(mRs) 4–6.
Additionally, the TTM trial sites were surveyed to rec-
ord which cooling device they used and other aspects of
their cooling practice, including their use of additional
cooling methods. The survey was administered using
commercially available subscription software (Survey-
Monkey®, Palo Alta, CA, USA).
Statistical analysis
Analyses were undertaken in STATA v.14 (Stata Statis-
tical Software, College Station, TX, USA). For baseline
characteristics, categorical variables are presented as
counts and percentage and were analysed using the chi-
square test, normally distributed data are expressed as
mean ± standard deviation (SD) and were analysed using
the Student’s t test and skewed data are expressed as
median and interquartile range [IQR] and were analysed
using the Wilcoxon's rank-sum test.
Performance and outcome data were analysed as clus-
tered (xtset) at the level of the TTM centres, within
which data existed. Continuous outcomes were analysed
using mixed effects regression (xtreg). Binary outcomes
were analysed using mixed effects logistic regression
(xtlogit). The number achieving temperature ever and
number out of range were analysed as over-dispersed
count data using mixed effects negative binomial regres-
sion (xtnbreg). Transformations were used to normalize
the continuous outcomes.
The analyses obtained estimates of the group differ-
ences, under the assumption of data missing completely
at random. No adjustment for potential confounders
was made for the treatment effects. All treatment effects
were produced using a fixed effects estimator (fe). Con-
tinuous outcomes are reported as Cohen’s d effect size
estimates, which used the pooled standard deviation.
Their confidence intervals were obtained through the
lincom post-estimation command. Effect sizes for the
binary and count data are reported as log-odds ratios
and log-risks ratios. All tests were two-tailed and a p
value of <0.05 was considered significant.
Results
Twenty-eight (77%) centres used SFC devices and ten
(28%) used IV. All IV centres used the Thermoguard
(Thermoguard, ZOLL Medical Corporation, Chelmsford,
MA, USA). There was variation among SFC centres and
some used more than one type: Arctic Sun, ten (Arctic
Sun, Medivance, Louisville, CO, USA); Blanketrol, five
(Blanketrol, Cincinnati Sub-Zero, Cincinnati, OH, USA);
Allon/Criticool, 11 (MTRE Advanced Technologies Ltd,
Rehovot, Israel) and other, four.
The cooling device was initiated in the intensive care
unit (ICU) in 31 centres with four starting in the emer-
gency department and one in the cardiac catheter la-
boratory. Additional conventional cooling (e.g. cold
fluids, ice packs) was used for induction with varying
frequency (always 26%; frequently 26%; occasionally
20%; rarely 11%; never 17%). Additional rescue cooling
was not commonly required (always 0%; frequently 0%;
occasionally 22%; rarely 36%; never 42%).
Of the 950 patients in the TTM trial, 934 were avail-
able for analysis having excluded those who were
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withdrawn (three in the 33 °C group, eight in the 36 °C
group) or did not have the device recorded (five in the
36 °C group). There were 240 (26%) IV versus 694 (74%)
SFC.
Baseline characteristics of the population are shown in
Table 1.
The mean ± SD temperature for IV and SFC devices
during the intervention are presented graphically (Figs. 1
and 2).
For the induction analysis, 195 patients were available
after exclusions. Results are shown in Table 2. Effect
estimates (Fig. 3) show that patients treated either with
SFC or IV took the same time to reach target
temperature (p = 0.58). No treatment difference was
detected for maximum cooling rate (p = 0.44). There was
no difference between the cooling devices in terms of
the number of patients achieving the target temperature
in 4 hours or ever during the intervention (p = 0.30 and
p = 0.47). Finally, although there were more episodes of
overcooling with SFC, the difference was not significant
(p = 0.15).
In the maintenance phase, 844 patients were available
for analysis. Results are shown in Table 2. Effect esti-
mates (Fig. 4) show that the cumulative deviation from
target temperature was significantly higher for the SFC
group (Cohen’s d effect size 0.59 (CI −0.91, −0.27; p <
0.001)). More patients in the SFC group were out of
range during maintenance (log-odds effect size −1.31 (CI
−2.24, −0.37; p = 0.006)) as was the median time out of
range (log-risks effect size −1.22 (CI −1.48, −0.97; p <
0.001)). A greater proportion of SFC patients had a
temperature >37.5 °C but this was not statistically
significant.
There was no statistically significant difference in any
of the adverse outcomes between the SFC and IV groups
(Fig. 5). The TTM trial primary outcome of all-cause
mortality at the end of the trial was the same in both
groups (46.3% in IV vs. 50.0% in SFC; p = 0.32). There
was no difference in the secondary trial outcomes of
CPC scale 3–5 (IV 49.0% vs. SFC 54.3%; p = 0.18) or
mRs 4–6 (IV 49.0% vs. SFC 53.0%; p = 0.48).
Discussion
In this study there was no difference between IV and
SFC in the induction phase of TTM. A maximum cool-
ing rate of 1.0 °C hr−1 was achieved in both groups.
Whilst rates up to 3 °C hr−1 have been claimed for some
devices [4, 14, 33], most studies have been in the region
of 1–1.5 °C hr−1, with similar performance between IV
and surface devices [10, 12, 19, 34, 35].
For patients managed at 33 °C, the median time to
achieve target temperature was similar. This represents
the time from randomization to target temperature and
includes the time taken to initiate cooling as well as the
time with cooling applied. Although all patients were
recruited within 4 hours of ROSC, we were unable to
determine the exact time that the cooling device was
started and there may have been a staggered start, as
many centres used additional cooling methods for in-
duction. Cold intravenous fluids may significantly reduce
the time to achieve target temperature [36, 37]. As such,
the cooling rate that we have reported may either under-
estimate (cooling device started later), or overestimate
(significant cooling effect from additional methods)
the actual device performance. Whilst we cannot ex-
clude an imbalance in the use of other cooling
methods between SFC and IV centres, our survey in-
dicated that additional cooling methods were applied
more commonly in the SFC centres than in IV (un-
published data). Whether this reflects random vari-
ation, or whether this is deliberate because of a
perception of inferior performance by SFC centres is
not known from this data. Any future studies of IV
versus SFC devices should rigorously control for the
use of additional cooling methods.
It is difficult to compare our data with the published
literature as other studies have used different targets and
have variably reported the start time as ROSC, hospital
admission or time when cooling started. Nevertheless,
Table 1 Baseline characteristics of the intravascular and surface
device patients
Characteristic Intravascular
n = 240
Surface device
n = 694
p value
Age (years) 63 ± 12.7 64.5 ± 12.0 0.12
Male gender 190, 79% 567, 82% 0.39
Body mass index (kg/m2) 26.9 ± 5.0 27.0 ± 8.1 0.78
Bystander witnessed 212, 89% 623, 90% 0.64
Bystander CPR 162, 68% 518, 74% 0.04
Shockable rhythm 187, 78% 547, 79% 0.78
Time to CPR (minutes) 1 [0–2] 1 [0–2] 0.37
Time to ROSC (minutes) 25 [17-39] 25 [17-40] 0.73
Time collapse to randomization
(minutes)
176 [125–227] 158 [114–210] 0.92
Baseline temperature on
admission (°C)
35.2 ± 1.2 35.3 ± 1.2 0.19
GCS 4 [3-5] 3 [3-5] 0.31
Serum pH 7.20 ± 0.15 7.20 ± 0.16 0.65
Serum lactate (mmol/l) 6.3 ± 4.3 6.9 ± 4.5 0.07
Circulatory shock on admission 42, 18% 94, 14% 0.13
Coronary angiography 181, 75% 404, 58% 0.27
Haemodialysis on day 1 9, 4% 21, 3% 0.50
SOFA - C 3 [2-4] 3 [2-4] 0.26
Values are mean ± SD, n,% or median [IQR] as appropriate
Abbreviations: CPR cardiopulmonary resuscitation, ROSC return of spontaneous
circulation, GCS Glasgow Coma Scale, SOFA - C Cardiovascular Sequential
Organ Failure Assessment
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median times of 190–450 minutes to achieve target are
reported [9, 18, 21, 24, 27, 33, 34, 38–40].
Delays to initiate cooling of between 1 and 3 hours
are common [24, 27, 34, 38–40] and this may be lon-
ger with IV than with conventional and/or surface
devices [27, 34].
Overall, there was no difference in the proportion of
patients reaching target temperature during the inter-
vention. Although only 60–65% of patients achieved tar-
get temperature within 4 hours, the TTM trial still
outperformed other OHCA trials. In the Hypothermia
after Cardiac Arrest study only 25% of patients reached
Fig. 1 Patient temperature for the 33 °C group over the intervention periods. Mean and standard deviation temperature (°C). Blue line and
shading is intravascular group, red line and shading is surface group. Time in hours
Fig. 2 Patient temperature for the 36 °C group over the intervention periods. Mean and standard deviation temperature (°C). Blue line and
shading is intravascular group, red line and shading is surface group. Time in hours
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a temperature <34 °C within 4 hours and almost 20%
never reached their target [39]. Time to reach target
may decrease with experience [9, 41].
Overcooling during the induction phase was propor-
tionally more common with SFC than with IV but the re-
sult was not statistically significant, possibly due to the
reduced numbers available for analysis. A recent study has
demonstrated a similar but significant result [25]. It is
known that overcooling is common when using conven-
tional cooling [17], and whilst this may be reduced using
SFC devices [16], there are significant differences between
different SFC technologies [11]. The clinical significance
of these overcooling events is not known. Overcooling of
up to 1 °C below target may be acceptable, provided that
the temperature remains greater than 30 °C [4]. We chose
to apply relatively strict criteria in order to explore subtle
differences in device performance. Is there an explanation
for possible inferior performance in SFC devices? One
theory is that it could relate to the modality of surface
cooling per se, because of a time lag in the equilibration of
temperature from the peripheral compartment to the core
where temperature is monitored. Alternatively, it may be a
function of the device feedback algorithms.
In this study, the IV group had significantly less devi-
ation from the target temperature during the mainten-
ance phase than the SFC group. Whether we analysed
the number of patients ever out of range, the time out of
range or the cumulative temperature deviation, all of
Table 2 Efficacy of the intravascular versus surface devices during induction and maintenance/rewarming phases
Performance metric Intravascular Surface device p value
Induction (33 °C group; n = 195); 52 intravascular versus 143 surface)
Time to target temperature (minutes) 210 [180] 240 [180] 0.58
Maximum cooling rate in induction phase (°C/hour) 1 [0.7] 1 [0.9] 0.44
Number of patients achieving target temperature in 4 hours 34, 65% 86, 60% 0.30
Number of patients achieving target temperature ever 52, [100] 140, [97] 0.47
Episodes of overcooling 4, 8% 49, 34% 0.15
Maintenance and rewarming (33 and 36 °C groups; n = 844); 226 intravascular versus 618 surface)
Cumulative deviation out of range (°C hours) 3.2 [5.0] 9.3 [8.0] <0.001
Number of patients out of range 127, 57.0% 568, 91.5% 0.006
Time out of range (hours) 1 [4.0] 8.0 [9.0] <0.001
Number of patients with temperature ≥37.5 °C 33 °C 4, 3% 41, 12% 0.44
36 °C 27, 23% 153, 47% 0.99
Values are n,% or median [IQR] as appropriate
Fig. 3 Performance of surface versus intravascular devices in induction phase. Effect estimates and 95% confidence intervals. SFC surface device,
IV intravascular
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these results were highly significant. This is consistent
with the published literature to date [19, 26]. The time
out of range for SFC is notably high; whilst this is influ-
enced by the relatively low tolerance of our definition
(0.5 °C), the cause may include lack of power in SFC
devices or the time lag in equilibration discussed above,
especially under conditions of vasoconstriction.
Temperature deviation is generally less than 1 °C and
the clinical significance of this is unclear. It has been
recommended that in the maintenance phase,
temperature should be tightly controlled, with minor or
no fluctuations (maximum 0.2 °C to 0.5 °C) but this is
not based on high-quality evidence [4]. In patients man-
aged at 33 °C, modest deviations will still remain within
the recommended range of 32–36 °C. However, in
patients managed at 36 °C, deviation may allow patients
to exceed the fever threshold. Even with the best tech-
nologies, there may be a small number of outliers with
Fig. 4 Performance of surface versus intravascular devices in maintenance phase. Effect estimates and 95% confidence intervals. SFC surface
device, IV intravascular
Fig. 5 Adverse events for surface versus intravascular devices. Effect estimates and 95% confidence intervals. SFC surface device, IV intravascular
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significant temperature deviation [38]. Despite a proto-
col designed to avoid fever in both arms, a quarter of
patients had one or more readings >37.5 °C. This was
more common in the 36 °C group as compared to 33 °C
group.
In this study, there was no statistically significant dif-
ference in adverse events, although there was a trend to-
wards more shivering and hypomagnesaemia in SFC
patients. Previous studies that have shown more shiver-
ing with surface devices [23, 24], perhaps related to the
role of cutaneous thermoreceptors in the shivering
reflex. Our findings contradict other studies, which have
demonstrated more electrolyte disturbance and sepsis
with IV cooling [24, 25]. The reasons for this are not
known, but could reflect the fact that experienced
centres in the TTM trial may have managed patients
with protocols for electrolyte management and prophy-
lactic antibiotics.
Data on adverse effects from cooling devices were not
specifically collected during the TTM trial. Reported
adverse events include skin damage [42, 43], deep vein
thrombosis [38, 44, 45] and bleeding [26, 34, 46]. The
safety profile of devices may influence clinician’s choice
and may influence performance if adverse events require
discontinuation. Any future studies should prospectively
collect data on the occurrence of these important
outcomes.
Mortality and poor neurological outcomes were not
significantly different between IV and SFC. This supports
previous literature, which shows no difference in levels
of biomarkers of neurological injury [26], or in outcome
[20, 24, 26, 27]. Whilst Oh and colleagues observed that
SFC was associated with poor neurological outcome and
increased hospital mortality when compared to IV, this
was no longer apparent after propensity score matching
[25]. The recent ICEREA study demonstrated that whilst
IV cooling was technically superior to basic external
cooling, it did not lead to statistically significant reduc-
tions in mortality [27]. Patient-centred outcomes related
to TTM devices may not be limited to the effect of body
temperature control or even to the incidence of clinical
side effects. As we have discussed, there may be complex
and compounding effects due to haemodynamic conse-
quences of vasoconstriction and shivering on the injured
brain or myocardium, unmeasured rheological effects, or
consequences of more rapid myocardial cooling. These
remain areas for further study.
The results of the TTM trial, and the recent change in
the ILCOR recommendation to a target temperature of
32–36 °C may, on the face of it, make any small differ-
ences in device performance during maintenance appear
less relevant. On the other hand, if more clinicians are
targeting 36 °C, accurate temperature control to avoid
the risk of pyrexia may be of greater importance.
This study is the largest to date, investigating the dif-
ference between SFC and IV devices. A wide range of
device-related metrics were analysed, and performance
was assessed at two different temperatures. Whilst this
was an observational study, the data was prospectively
collected as part of a high-quality randomized controlled
trial. Because all centres were experienced in TTM, and
selected the device according to their own preference, it
is likely that they had significant experience of the device
and as such use should have been optimal. This study is
investigator led and received no commercial or industry
funding.
This study has limitations. As with all observational
studies, there is a risk of confounding due to unmeas-
ured differences and other factors which influence
patient temperature may have varied (e.g. sedation or
neuromuscular blockade, selection of catheters, pads or
blankets, troubleshooting device problems or additional
cooling methods).
Whilst the TTM trial was very well conducted, the
data set was not fully complete and a number of patients
were excluded due to missing data. The authors acknow-
ledge that the random effects estimator is more efficient,
however, lack of adequate data on both the individual
and cluster levels led to the choice of the fixed effects
estimator, which is more robust against selection bias.
Finally, we have analysed cooling devices by category
rather than comparing proprietary devices because we
did not have patient-level data on specifically which de-
vice was used. It is possible that there is heterogeneity
between different SFC devices and this study cannot ex-
clude differences in performance between the SFC de-
vices used. The study was not designed to compare
intravascular or surface devices with basic external cool-
ing and whilst there is evidence that this is logistically
and technically inferior, it does remain in use in some
centres.
Conclusions
In patients who remain comatose following successful
resuscitation after OHCA, TTM may be applied with
either intravascular or surface cooling devices. Intravas-
cular and surface cooling was equally effective during
the induction of mild hypothermia. However, surface
cooling was associated with less precision during the
maintenance phase. Although the clinical significance of
this is not known, this may have implications for the
management of patients at 36 °C. There was no statisti-
cally significant difference in adverse events, mortality or
poor neurological function between patients treated with
intravascular and surface cooling devices.
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